These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 35309350)

  • 1. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
    Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
    Front Immunol; 2022; 13():801909. PubMed ID: 35309350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predict progression free survival and overall survival using objective response rate for anti-PD1/PDL1 therapy development.
    Yang L; Raveendran G; Meng X; Lin J; Meng Z
    BMC Cancer; 2024 Jul; 24(1):912. PubMed ID: 39075397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.
    Mo DC; Luo PH; Huang SX; Wang HL; Huang JF
    Int Immunopharmacol; 2021 Feb; 91():107281. PubMed ID: 33338862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer.
    Zhang X; Yin WJ; Zhang AL; Zhang XX; Ding LJ; Zhang J; He ST; Yan JP
    J Obstet Gynaecol; 2024 Dec; 44(1):2390564. PubMed ID: 39150330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
    Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
    J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies.
    Gao RL; Song J; Sun L; Wu ZX; Yi XF; Zhang SL; Huang LT; Ma JT; Han CB
    Front Pharmacol; 2022; 13():920165. PubMed ID: 36034821
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
    Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
    Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
    Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
    Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis.
    Xian F; Wu J; Zhong L; Xu G
    Medicine (Baltimore); 2023 Mar; 102(10):e33204. PubMed ID: 36897735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.
    Chen J; Lu W; Chen M; Cai Z; Zhan P; Liu X; Zhu S; Ye M; Lv T; Lv J; Song Y; Wang D
    Ther Adv Med Oncol; 2024; 16():17588359231225036. PubMed ID: 38420602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data.
    Ying J; Chen J
    Crit Rev Oncol Hematol; 2019 Jul; 139():134-142. PubMed ID: 30979533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis.
    Yang Y; Jin G; Pang Y; Huang Y; Wang W; Zhang H; Tuo G; Wu P; Wang Z; Zhu Z
    Front Pharmacol; 2020; 11():40. PubMed ID: 32116716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
    Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
    Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials.
    Liu Q; Zhang Y; Liu M; Xu R; Yi F; Wei Y; Zhu S; Zhang W
    World J Surg Oncol; 2021 Oct; 19(1):298. PubMed ID: 34645484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of immune checkpoint inhibitors related to pulmonary adverse events: a retrospective analysis of clinical studies and network meta-analysis.
    Hong B; Du B; Chen R; Zheng C; Ni R; Liu M; Yang J
    BMC Med; 2024 Feb; 22(1):75. PubMed ID: 38373990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer.
    Zhang T; Zhu C; Zhang N; Zhang L; Wang S; Xun Z; Xu Y; Yang X; Lu X; Zhao H
    Int Immunopharmacol; 2024 Mar; 129():111642. PubMed ID: 38325044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of EGFR-TKI in recurrent/metastatic nasopharyngeal carcinoma patients: A systematic review and meta-analysis.
    An Z; He L; Chen T; Liang B; Wu Q
    Laryngoscope Investig Otolaryngol; 2024 Jun; 9(3):e1279. PubMed ID: 38803463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
    Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
    Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis.
    Wang F; Wang FH; Sun K; Jiang C; Peng S; Xu LX; Kuang M; Guo GF; Chen SL
    J Inflamm Res; 2022; 15():6031-6046. PubMed ID: 36339826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis.
    Yeo BSY; Song HJJMD; Soong YL; Chua MLK; Ang MK; Lim DWT; See A; Lim CM
    Oral Oncol; 2023 Jan; 136():106242. PubMed ID: 36413976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.